









Atlas Genet Cytogenet Oncol Haematol. 2008;12(1)  44 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology                         
                         OPEN ACCESS JOURNAL AT INIST-CNRS 
JAK3 (janus kinase 3 or just another kinase 3) 
Ping Shi, Hesham M Amin 
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe 
Blvd, Houston, TX 77030, USA 
Published in Atlas Database: July 2007 
Online updated version: http://AtlasGeneticsOncology.org/Genes/JAK3ID41032ch19p13.html  
DOI: 10.4267/2042/38474 
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. 




Other names: JAK-3; JAK_HUMAN; L-JAK; LJAK; 
EC 2.7.10.2 
Location: 19p13.1 
Local order: chr19: 17788,324-17819800. 
DNA/RNA 
Description 
JAK3 is a functioning gene that comprises 23 exons 
spanning roughly 21 kb of genomic DNA with an open 
reading frame of 3372 bp. 
Transcription 
4025 bp mRNA. 7 transcript variants encoding 7 
distinct proteins. 
Protein 
Note: 3 isoforms produced by alternative splicing: 
JAK3S, JAK3B, JAK3M. 
Description 
1124 amino acids, 125099 Da. JAK3 is comprised of 7
JAK homology (JH) domains. JH1 contains the C 
terminus kinase domain and an SH2 or SH3 binding 
motif; JH2 contains a pseudokinase domain tandemly 
linked to the N site of the JH1 domain; 5 more JH 
domains. The N terminus region (JH6 and JH7) is 
critical for receptor binding and signal transduction. 
Expression 
JAK3 is expressed in 12 normal human tissues (bone 
marrow, spleen, thymus, brain, spinal cord, heart, 
skeletal muscle, liver, pancreas, prostate, kidney, and 
lung). JAK3S is more commonly seen in hematopoietic 
cells, whereas JAK3B and JAK3M are detected in cells 
of hematopoietic or epithelial origin. 
Localisation 
Intracellular, membrane-associated through associati n 
with interleukin (IL) receptor common gamma chain 
(gamma-c). 
Function 
Tyrosine kinase of the non-receptor type. Involved in 
the signaling of ILs that contain the gamma-c chain in 
their respective receptors, including IL-2, IL-4, IL-7, 
IL-9, IL-15, and IL-21. Induces tyrosine 
phosphorylation of a number of proteins, of which most 
widely studied are signal transducers and activators of 
transcriptions (STAT). JAK3 has also been shown to 
phosphorylate insulin receptor substrate-1 (IRS-1), 
IRS-2, and PI3K/Akt. 
Homology 
JAK3 is the most recently identified member of the 
mammalian Janus kinase subfamily (TYK2, JAK1, 
JAK2, and JAK3); JAK3 paralogs to JAK1 and JAK2; 
human JAK3 orthologs to murine Jak3. 
Mutations 
Note: Mostly point mutations were identified affecting 
all 7 structural JH domains of JAK3. 
Somatic 
Mutations of JAK3 were generally associated with the
same cellular phenotype of the more frequently 
encountered X-linked SCID due to gamma-c 
deficiency. It was confirmed with the identification of 
34 mutations in JAK3-SCID patients from Europe and 
the US. JAK3-SCID is inherited as autosomal recessiv  
disease. It is estimated to account for approximately 7-
14% of heritable SCID. JAK3 mutations are seemingly 
sporadic, and neither preferential gene locations (i.e.
gene 'hot-spots') nor founder effects have yet been 
documented. 
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Different mutations identified in all of the 7 domains of JAK3. The mutations in 'black color' are the mutations reported in JAK3-SCID; 
'red color and italic' identifies mutations reported in acute megakaryoblastic leukemia; and 'orange color and underline' highlights one 
mutation that has been reported in both JAK3-SCID and acute megakaryoblastic leukemia. 
The majority of JAK3-SCID patients are compound 
heterozygotes, having inherited a distinct mutation 
from each parent, although some individuals are 
homozygous for their mutations as a result of parent l 
consanguinity. Most mutations have dramatic effects 
on protein expression of JAK3, but some missense  
mutations or small in-frame deletions allow for some 
protein expression. These mutations affect kinase 
activity, receptor binding, and intracellular trafficking. 
In addition, 7 mutations of JAK3 have been recently 
described in 5 patients with acute megakaryoblastic 
leukemia with or without Down syndrome. These 
mutations are in general activation mutations. The 
Down syndrome patients presented initially with 
transient myeloproliferative disease. 
Implicated in 
Severe combined immunodeficiency 
(SCID) 
Note: 34 unique mutations of JAK3 have been 
identified in cases of JAK3-SCID, occurring in all of its 
7 structural JH domains. No hotspots have been 
reported and multiple types of mutations have been 
identified: 21 missense/nonsense mutations, 7 splice 
site mutations, 3 small deletions, 2 gross deletions a d 
1 insertion. 
Disease 
Defects in JAK3 are associated with the autosomal  
recessive T-cell negative/B-cell positive type of severe 
combined immunodeficiency (SCID); a condition 
characterized by the absence of circulating mature T-
lymphocytes and NK cells, normal to elevated numbers 
of nonfunctional B-lymphocytes, and marked 
hypoplasia of lymphoid tissues. 
Prognosis 
SCID due to JAK3 deficiency is generally a lethal 
disorder. The advent of hematopoietic stem cell 
transplant revolutionized the outcome of JAK3-SCID, 
and at present it is still the treatment of choice. 
Acute megakaryoblastic leukemia 
Note: 7 unique mutations of JAK3 have also been 
identified in patients with acute megakaryoblastic 
leukemia. These mutations occur in the JH2, JH6, and 
JH7 domains. 
Disease 
Also, defects in JAK3 have been recently described in 
some cases of acute megakaryoblastic leukemia with or 
without Down syndrome. Acute megakaryoblastic 
leukemia is a type of acute leukemia where more than
50% of the blasts are of megakaryocytic lineage. The
exact role of JAK3 in this disease is not completely 
known. 
Prognosis 
Acute megakaryoblastic leukemia demonstrates a bad 
clinical outcome. 
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